all pitches
Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies. The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs ...
MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug ...
MagForce Nanotechnologies AG is the global leader in the field of nanotechnology cancer treatment. This revolutionary technology aims to establish a entirely new form of cancer treatment within the near future, using magnetic particles to treat tumors with very minimal side effects, thus enhancing patient quality of life. The technology and its related equipment are ...
WILEX is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. The Company was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX’s mission is to develop drugs with a low side effect profile and targeted ...
PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which ...
Cancer is a dreaded and often fatal disease. However, given today’s treatment options, outcomes could potentially be greatly improved if more cancers were detected in early stages and treatments were better tailored to individual patients’ needs. This widely unmet medical need makes IVD (in vitro diagnostic) tests for cancer a segment with high future growth ...
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative treatments to improve the lives of patients with high unmet medical needs. Our mission is to build a top-tier profitable biopharmaceutical company founded on the successful development and commercialisation of novel gene-based medicines. Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected ...
Response Biomedical develops, manufactures and markets rapid point-of-care (POC) diagnostic tests for use with our proprietary RAMP® (Rapid Analyte Measurement Platform) System for clinical and environmental applications. RAMP® has set a new performance standard in rapid diagnostic testing by providing lab quality information in minutes. For more information, visit: http://www.responsebio.com
Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The company's lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney and thyroid. The treatment of bone metastases represents an area of high unmet medical need. Algeta's pipeline is built on ...
YM BioSciences, 60sec
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization. The Company is currently ...